Promising Directions in Hematologic Malignancies: A Nurse's Guide to Novel Treatments for AML, CLL, and NHL
It is crucial that nurses working with these patient populations havecurrent education on emerging therapies, including their mechanisms of action,expected outcomes, and associated adverse events. To address the need forcurrent education on novel therapies for AML, CLL and NHL, Robert MichaelEducational Institute LLC (RMEI) and Postgraduate Institute for Medicine (PIM)have jointly sponsored a free continuing education activity that includes aMonograph and Learning Assessment. This activity supported by an educationalgrant from Cephalon, Inc.
Faculty involved in the development of this educational activity includeArchie Bleyer, MD, Clinical Research Professor at the Oregon Health & ScienceUniversity School of Medicine in Portland, Oregon, as well as oncology nursesfrom leading academic institutions across the country.
Healthcare professionals can download a copy of this self-study activityby visiting http://www.RMEI.com/bloodcancermonograph .
"Quality continuing medical education is vital to developing andincreasing knowledge and skills and enhancing patient care," says RMEIPresident and CEO, Robert M. Colleluori.
RMEI is a full-service medical education company dedicated to providingcomprehensive medical education to healthcare providers. The goal of allaccredited RMEI educational activities is to promote a spirit of lifelonglearning and continuous professional development. RMEI works closely withmedical experts to design activities that improve diagnosis and treatment.These activities include national and international symposia, teleconferences,live meetings, enduring print materials, and interactive Internet programs.
For additional educational activities, please visit www.RMEI.com.
SOURCE Robert Michael Educational Institute LLC
You May Also Like